Drugs / ND-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06360874 | May → Dec 2024 | — | Shenzhen NewDEL Biotech, Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06169579 | Feb 2024 → Dec 2025 overdue | neoplasm | Shenzhen NewDEL Biotech, Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ND-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360874 ↗ |
| Action | Inhibit | “inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection)” NCT06169579 ↗ |
| Modality | Small molecule | “small molecular inhibitor” NCT06169579 ↗ |
| Route | Oral | “ND-003 tablets will be administered orally” NCT06169579 ↗ |